TABLE OF CONTENTS
Volume 78, Issue 5 (November 2005)
Clinical Trials |
Pharmacodynamics and Drug Action |
Pharmacokinetics and Drug Disposition |
Pharmacodynamics and Drug Action |
Pharmacogenetics and Genomics |
Correction |
Pharmacogenetics and Genomics
Commentaries
Women in early-phase clinical drug trials: Have things changed over the past 20 years?
Jeanette Fleisch MD, Markus C. Fleisch MD and Petra A. Thürmann MD
Clin Pharmacol Ther 78: 445-452; doi:10.1016/j.clpt.2005.08.016
Why a nicotine vaccine?
Jacques Le Houezec PhD
Clin Pharmacol Ther 78: 453-455; doi:10.1016/j.clpt.2005.08.008
Clinical Trials
Safety and immunogenicity of a nicotine conjugate vaccine in current smokers
Dorothy K. Hatsukami PhD, Stephen Rennard MD, Douglas Jorenby PhD, Michael Fiore MD, MPH, Joseph Koopmeiners, Arjen de Vos MD, PhD, Gary Horwith MD and Paul R. Pentel MD
Clin Pharmacol Ther 78: 456-467; doi:10.1016/j.clpt.2005.08.007
Anti-inflammatory effects of clopidogrel intake in renal transplant patients: Effects on platelet-leukocyte interactions, platelet CD40 ligand expression, and proinflammatory biomarkers
Jochen Graff MD, Sebastian Harder MD, Oliver Wahl, Ernst-Heinrich Scheuermann MD and Jan Gossmann MD
Clin Pharmacol Ther 78: 468-476; doi:10.1016/j.clpt.2005.08.002
A pilot study indicating that bradykinin B2 receptor antagonism attenuates protamine-related hypotension after cardiopulmonary bypass
Mias Pretorius MBChB, MSc, Frank G. Scholl MD, Julie A. McFarlane RN, Laine J. Murphey MD, PhD and Nancy J. Brown MD
Clin Pharmacol Ther 78: 477-485; doi:10.1016/j.clpt.2005.08.010
Pharmacodynamics and Drug Action
Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation
Pamala Jacobson PharmD, John Rogosheske PharmD, Juliet N. Barker MB, BS, Kathleen Green PharmD, Juki Ng PharmD, Daniel Weisdorf MD, Ye Tan MS, Janel Long BS, Rory Remmel PhD, Ronald Sawchuk PhD and Philip McGlave MD
Clin Pharmacol Ther 78: 486-500; doi:10.1016/j.clpt.2005.08.009
Sustained 24-hour blockade of the renin-angiotensin system: A high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor
Christopher Hasler MD, Jürg Nussberger MD, Marc Maillard PhD, Andrei Forclaz MD, Hans R. Brunner MD and Michel Burnier MD
Clin Pharmacol Ther 78: 501-507; doi:10.1016/j.clpt.2005.08.001
Pharmacokinetics and Drug Disposition
A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc
Maria C. Rosario PhD, Philippe Jacqmin PhD, Pat Dorr PhD, Elna van der Ryst MBChB, PhD and Chris Hitchcock PhD
Clin Pharmacol Ther 78: 508-519; doi:10.1016/j.clpt.2005.07.010
Pharmacodynamics and Drug Action
Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients
Sun Min Jung MD, Kyoung-Ah Kim PhD, Hyun-Kee Cho MD, PhD, Il Geun Jung MD, Pil-Whan Park MD, PhD, Won Tan Byun MD, PhD and Ji-Young Park MD, PhD
Clin Pharmacol Ther 78: 520-528; doi:10.1016/j.clpt.2005.07.007
Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam
Harshvardhan N. Chaobal DO and Evan D. Kharasch MD, PhD
Clin Pharmacol Ther 78: 529-539; doi:10.1016/j.clpt.2005.08.004
Pharmacogenetics and Genomics
Several-fold increase in risk of overanticoagulation by CYP2C9 mutations
Jonatan D. Lindh MD, Stefan Lundgren PhD, Lennart Holm RN, Lars Alfredsson PhD and Anders Rane MD, PhD
Clin Pharmacol Ther 78: 540-550; doi:10.1016/j.clpt.2005.08.006
Correction
Top of pagePharmacogenetics and Genomics
The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment
Marilu Fiegenbaum PhD, Fabiano R. da Silveira BSc, Cézar R. Van der Sand MD, Luiz Carlos Van der Sand MD, Maria E. W. Ferreira MD, Renan C. Pires MD and Mara H. Hutz PhD
Clin Pharmacol Ther 78: 551-558; doi:10.1016/j.clpt.2005.08.003
